Atox Bio’s technology is licensed from the Hebrew University of Jerusalem. Atox Bio has the worldwide exclusive license for the Intellectual Property. The company has filed PCTs covering the composition of matter, the use of superantigen antagonist and modulators of co-stimulation technology. First two patents granted, two additional patent applications are now in national phase.